前列腺癌领域2020年必读的几篇关键研究

2021-02-17 MedSci原创 MedSci原创

欧洲泌尿外科协会(EAU)2021年肿瘤泌尿科(ESOU)虚拟会议的发表了2020年以来泌尿外科肿瘤必读论文,讨论了与之相关的重要论文前列腺癌。

欧洲泌尿外科协会(EAU)2021年肿瘤泌尿科(ESOU)虚拟会议的发表了2020年以来泌尿外科肿瘤必读论文,讨论了与之相关的重要论文前列腺癌。 第一篇论文是《新英格兰医学杂志》上发表的“针对前列腺癌的MRI靶向,系统性和联合活检”。1该论文评估了进行针对活检的磁共振成像(MRI)是否可以减少MRI可见病变男性前列腺癌分类错误。根据等级组,共有2103名患有MRI可见前列腺病变的男性接受了MRI靶向活检和系统活检,其主要检测结果为癌症。此外,在随后进行前列腺癌根治术的男性中,记录了从活检到手术标本的全组织病理学分析的等级组的升级和降级。作者发现,通过两种方法的组合,诊断出癌症的人数为1,312(62.4%),而404名男性(19.2%)接受了前列腺癌根治术。 MRI靶向活检的癌症检出率显着低于系统活检,对于第1级癌症,而在第3至5级组则显着更高(p <0。)。联合活检导致癌症诊断的男性比单独使用任一种方法的多208人(9.9%),并升级为458名男性(21.8%)的高年级组。但是,如果仅进行了MRI靶标活检,则将有8.8%的临床重要癌症(≥3级组)被错误分类(详细见:NEJM:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2022-05-14 jiaqilei

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2022-02-06 120d5e71m96(暂无昵称)

    学习新知识

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-04-07 ms4000001145982604

    看看~~~~~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-03-25 ms9000000127731620

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-02-24 ms5000001490001625

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-02-18 ms9000002077625059

    来学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-02-17 健康达人
  8. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-02-17 wxl882001

    了解

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-02-17 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1219569, encodeId=f93f121956916, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=395f2314684, createdName=jiaqilei, createdTime=Sat May 14 13:57:21 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190562, encodeId=e5d911905623f, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Sun Feb 06 19:06:11 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955083, encodeId=2e9e955083ac, content=看看~~~~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dcf5477983, createdName=ms4000001145982604, createdTime=Wed Apr 07 22:46:49 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950911, encodeId=73c995091193, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c135472925, createdName=ms9000000127731620, createdTime=Thu Mar 25 07:36:43 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926966, encodeId=c9c69269661c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8015420022, createdName=ms5000001490001625, createdTime=Wed Feb 24 22:10:26 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925345, encodeId=5b4592534519, content=来学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af065460960, createdName=ms9000002077625059, createdTime=Thu Feb 18 21:09:40 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925148, encodeId=81a7925148dc, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:23 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925121, encodeId=a2f392512125, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Feb 17 20:39:46 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040961, encodeId=8b9410409614a, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Feb 17 19:08:55 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925097, encodeId=f2ab92509e7b, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:56:00 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-02-17 jyzxjiangqin

    好文章!

    0

相关资讯

JAMA Oncol:22基因基因组分类器可预测前列腺癌术后远处转移风险!

Decpher(Decpher Biosciences Inc)是一种基因组分类器(GC),用于评估前列腺癌患者前列腺癌根治术(RP)后发生远处转移(DM)的风险。

Cell Death Dis:前列腺癌微环境中雄激素受体/丝胺A复合物的靶向作用

前列腺癌是男性癌症相关死亡的主要原因,患者经常出现耐药性和转移性疾病。大多数研究集中在与雄激素受体突变有关或与前列腺癌细胞过度激活信号通路的获得特性有关的激素耐药机制。肿瘤微环境在前列腺癌的进展中起着

Commun Biol:循环细胞外小体释放致癌性miR-424

细胞外小体(EVs)是细胞间信号转移的相关手段,能够促进致癌刺激的传播以及癌症患者的疾病演变和转移的扩散。

ASCO GU 2021: ctDNA检测能有效判断Olaparib对去势抵抗性前列腺癌效果(PROfound研究)

在转移性去势抵抗性前列腺癌(mCRPC)中,同源重组修复(HRR)通路基因突变(如BRCA1和BRCA2)有更强的疾病侵袭性和更高的死亡率。这类基因突变对聚二磷酸腺苷核糖聚合酶(PARP)抑制剂更敏感

ASCO GU 2021:前列腺癌的免疫治疗取得曙光

近年来,以PD-1/PD-L1单抗为代表的免疫检查点抑制剂先后在多个瘤种获得突破,包括黑色素瘤,淋巴瘤,NSCLC,肝癌,乳腺癌等。但是在晚期前列腺癌中,探索相对较晚。虽然,K药等获得“普

ASCO GU 2021:nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关(PROSPER试验)

自2018年春季以来,针对非转移性去势抵抗性前列腺癌(nmCRPC)的患者的治疗选择有了快速发展。直到提出SPARTAN和PROSPER试验为止,据报道,在2007年的nmCRPC中使用了阿帕鲁胺和恩